Acute Coronary Syndrome (ACS) represents a spectrum of conditions characterized by decreased blood flow to the heart muscle. Its management has witnessed significant advancements over the years, with best practices evolving continuously in the light of new evidence.
One of the most significant advancements in ACS management is the increased use of high-sensitivity cardiac troponin (hs-cTn) assays. These tests allow for earlier and more accurate diagnosis of myocardial injury. Additionally, the adoption of radial access over femoral for coronary angiography and interventions has reduced the risk of bleeding complications.
Pharmacological management of ACS has also improved, with dual antiplatelet therapy (DAPT) using newer P2Y12 inhibitors, like ticagrelor and prasugrel, showing better outcomes than older drugs. Moreover, the introduction of novel anticoagulants has provided additional options for managing patients with ACS.
Non-pharmacological management, including lifestyle modifications and cardiac rehabilitation, is now an integral part of ACS management. Emphasis on smoking cessation, diet control, and regular exercise has shown to improve long-term outcomes in ACS patients.
Personalized care is becoming increasingly important in ACS management. Risk stratification using tools like the GRACE score can guide treatment decisions. Furthermore, genetic testing can help predict response to certain medications, enabling a more tailored approach to therapy.
In conclusion, the management of ACS has come a long way, with advancements in both pharmacological and non-pharmacological strategies. However, the key to successful ACS management lies in the adoption of best practices, personalized care, and a multidisciplinary approach.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation